Novartis removed top executives at its Japan subsidiary and apologized for recent problems including improprieties in a doctor-led leukemia clinical trial research program revealed in an independent panel report released April 2.
David Epstein, division head of Novartis Pharmaceuticals, said the company was swapping out top management because it wanted a new team of executives who will operate the company “in a fully compliant and ethical manner.”
Dirk Kosche will replace Yoshiyasu Ninomiya as head of Novartis Pharma K.K., Francis Bouchard fills the job of Kazuo Asakawa as head of oncology and Michael Ferris will take over Hiroko Ishikawa’s position ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.